Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

Share Price is delayed by 15 minutes
Get Live Data
8.65    0.00 (0.00%)
Bid:
8.30
Ask:
9.00
Spread: 0.70 (8.434%)
Market Cap: £18.86m
IXI Live PriceLast checked at - London Stock Exchange

Intraday Ixico Share Chart

PDMR Transaction

25 Mar 2021 09:14

RNS Number : 4793T
IXICO plc
25 March 2021
 

25 March 2021

 

IXICO plc

("IXICO" or the "Company")

 

Director/PDMR Dealing

 

 

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that Mark Warne, Non-Executive Director, today purchased 14,250 ordinary shares in the Company at an average price of 63 pence.

 

 

For further information please contact:

 

IXICO plc +44 20 3763 7499

Giulio Cerroni, Chief Executive Officer

Grant Nash, Chief Financial Officer

 

Cenkos Securities plc (Nominated adviser and sole broker) +44 20 7397 8900

Giles Balleny / Max Gould (Corporate Finance)

Michael F Johnson / Russell Kerr (Sales)

 

Walbrook PR Ltd

+44 (0)20 7933 8780

 

Paul McManus / Lianne Cawthorne /

IXICO@walbrookpr.com

Alice Woodings

 

The below makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Mark Warne

2

Reason for notification

On market purchase

a.

Position/Status

Non-Executive Director

b.

Initial notification/

Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

IXICO plc

b.

LEI

2138005M1F59O6HWSA97

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrumentIdentification Code

Ordinary shares of 1p each

ISIN: GB00BCLY7L40

 

b.

Nature of the transaction

 Purchase of ordinary shares

c.

Price(s) and volume(s)

Price(s) per share

Volume(s)

£0.66

250 shares

£0.64

1500 shares

£0.65

1500 shares

£0.63

1500 shares

£0.61

1500 shares

£0.61

1500 shares

£0.63

1500 shares

£0.62

5000 shares

 

 

d.

Aggregated information

- Aggregated Volume

- Price

 

14,250 shares

£0.63

e.

Date of the transaction

24 March 2021

f.

Place of the transaction

London Stock Exchange, AIM Market

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHKELBLFXLBBBK
Date   Source Headline
8th Jun 20267:00 amRNSScientific advisors & partners update
22nd May 20267:00 amRNS-RCompany presentation at Mello 2026
21st May 20267:00 amRNSContract win and contract extension
19th May 20267:00 amRNSInterim results for six months ending 31/03/2026
12th May 20267:00 amRNSIXICO Updates AI Neuroimaging Platform
28th Apr 20262:31 pmRNSHolding(s) in Company
28th Apr 20261:50 pmRNSHolding(s) in Company
28th Apr 202611:45 amRNSHolding(s) in Company
28th Apr 202610:49 amRNSHolding(s) in Company
27th Apr 20264:02 pmRNSHolding(s) in Company
27th Apr 20263:57 pmRNSHolding(s) in Company
27th Apr 20263:55 pmRNSHolding(s) in Company
27th Apr 20261:51 pmRNSHolding(s) in Company
27th Apr 202611:13 amRNSHolding(s) in Company
24th Apr 20263:30 pmRNSHolding(s) in Company
22nd Apr 202612:40 pmRNSIssue of Equity
21st Apr 20267:00 amRNSTrading Update
16th Apr 202612:01 pmRNSResult of GM and Update on Issue of Equity
7th Apr 20261:14 pmRNSResult of Retail Offer
31st Mar 20267:01 amRNSRetail Offer
31st Mar 20267:00 amRNSPlacings and Subscription
26th Mar 20267:00 amRNSCollaboration with Medidata
26th Feb 20267:00 amRNSValidation of Neuroimaging Technology Platform
12th Feb 20268:48 amRNSCorrection: c.£1.5 million Contract Extension
12th Feb 20267:00 amRNSc.£1.5 million Contract Extension
5th Feb 20267:00 amRNSAppointment of Chief Commercial Officer
23rd Jan 20265:05 pmRNSResults of AGM
9th Dec 20257:05 amRNSShare option award
9th Dec 20257:00 amRNSFinancial Results for year ended 30 September 2025
1st Dec 20257:00 amRNSOperational Update
27th Nov 20257:00 amRNSNotice of 2025 Full Year Results and IMC
17th Nov 20257:00 amRNSClinical Trial Contract Win
3rd Nov 20252:30 pmRNSCapital Markets Day Presentation and Video
16th Oct 20257:00 amRNSTrading Update
15th Oct 20257:00 amRNSNew contract win and contract extension
30th Sep 20257:00 amRNSNotice of Capital Markets Day
12th Aug 20257:00 amRNSContract Win
22nd Jul 20257:00 amRNSStrategic Data Partnership with GAP
17th Jul 20257:00 amRNSTrading Update
13th Jun 20258:03 amRNSShare option awards and PDMR Dealing
10th Jun 20257:00 amRNSFDA Clearance of Alzheimer's Diagnostic Biomarker
20th May 20256:00 pmRNSHolding(s) in Company
20th May 20257:00 amRNSHalf-year Report
8th May 202511:30 amRNSHolding(s) in Company
6th May 20257:00 amRNSNotice of Interim Results & Investor Presentation
16th Apr 20257:00 amRNSTrading Update
27th Feb 20257:00 amRNSContract Win
12th Feb 20257:00 amRNSFurther Validation of IXICO’s AI Imaging Platform
7th Feb 20253:00 pmRNSIssue of share options and PDMR dealing
24th Jan 20252:16 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.